Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease

Journal of Medicinal Chemistry

Volumn 60, Issue 5, 2017, Pages 1843-1859

  Nirogi, Ramakrishna ^a   Shinde, Anil ^a   Kambhampati, Rama Sastry ^a   Mohammed, Abdul Rasheed ^a   Saraf, Sangram Keshari ^a   Badange, Rajesh kumar ^a   Bandyala, Thrinath Reddy ^a   Bhatta, Venugopalarao ^a   Bojja, Kumar ^a   Reballi, Veena ^a   Subramanian, Ramkumar ^a   Benade, Vijay ^a   Palacharla, Raghava Choudary ^a   Bhyrapuneni, Gopinadh ^a   Jayarajan, Pradeep ^a   Goyal, Vinod ^a   Jasti, Venkat ^a  

^a SUVEN LIFE SCIENCES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 BROMOPHENYL)SULFONYL] 5 METHOXY 3 [(4 METHYL 1 PIPERAZINYL)METHYL] 1H INDOLE DIMESYLATE MONOHYDRATE; ACETYLCHOLINE; CYTOCHROME P450 3A4; IDALOPIRDINE; LIGAND; NEUROPROTECTIVE AGENT; PIPERAZINE; PROSTAGLANDIN; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; SULFONAMIDE; UNCLASSIFIED DRUG; 1-((2-BROMOPHENYL)SULFONYL)-5-METHOXY-3-((4-METHYL-1-PIPERAZINYL)METHYL)-1H-INDOLE DIMESYLATE MONOHYDRATE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN 6 RECEPTOR; SEROTONIN RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PENETRATION; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTRIC POTENTIAL; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; REACTION OPTIMIZATION; SUBSTITUTION REACTION; SYSTEMIC CIRCULATION; VENTRAL HIPPOCAMPUS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; MALE; ORAL DRUG ADMINISTRATION; RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; DRUG DISCOVERY; HUMANS; INDOLES; MALE; PIPERAZINES; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 85015060746     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01662     Document Type: Article

References (55)

1. Alzheimer’s disease facts and figures; Alzheimer’s association 2016; Alzheimer’s Disease International: London, UK, https://www.alz.co.uk/research/world-report-2016 (accessed October 10, 2016).
2. Anand, R.; Gill, K. D.; Mahdi, A. A. Therapeutics of Alzheimer’s disease: Past, present and future Neuropharmacology 2014, 76, 27-50 10.1016/j.neuropharm.2013.07.004
3. Thompson, S.; Lanctôt, K. L.; Herrmann, N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease Expert Opin. Drug Saf. 2004, 3, 425-440 10.1517/14740338.3.5.425
4. Johnson, C. N.; Roland, A.; Upton, N. New symptomatic strategies in Alzheimer’s disease Drug Discovery Today: Ther. Strategies 2004, 1, 13-19 10.1016/j.ddstr.2004.08.003
5. Birks, J. Cholinesterase inhibitors for Alzheimer’s disease Cochrane Database Syst. Rev. 2006, 25, CD005593 10.1002/14651858.CD005593
6. Cacabelos, R.; Takeda, M.; Winblad, B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease Int. J. Geriatr. Psychopharmacol. 1999, 14, 3-47 10.1002/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7
7. Schneider, L. S.; Dagerman, K. S.; Higgins, J. P.; McShane, R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease Arch. Neurol. 2011, 68, 991-998 10.1001/archneurol.2011.69
8. Monsma, F. J., Jr.; Shen, Y.; Ward, R. P.; Hamblin, M. W.; Sibley, D. R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs Mol. Pharmacol. 1993, 43, 320-327
9. 6 medicinal chemistry Int. Rev. Neurobiol. 2010, 94, 1-34 10.1016/B978-0-12-384976-2.00001-0
10. 6 receptor ligands with therapeutic potential Prog. Med. Chem. 2009, 48, 163-224 10.1016/S0079-6468(09)04805-X
11. 6 antagonists as potential treatment for cognitive dysfunction Drug Dev. Res. 2009, 70, 145-168 10.1002/ddr.20293
12. 6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders Pharmacol. Ther. 2008, 117, 207-231 10.1016/j.pharmthera.2007.08.006
13. 6 receptors for the treatment of Alzheimer’s disease Expert Opin. Invest. Drugs 2015, 24, 1515-1528 10.1517/13543784.2015.1102884
14. 6 receptor antagonist, Ro 04-6790, in rats Br. J. Pharmacol. 1999, 126, 1537-1542 10.1038/sj.bjp.0702445
15. 6 receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating Eur. Neuropsychopharmacol. 2007, 17, 277-288 10.1016/j.euroneuro.2006.06.009
16. 6 receptor antagonist, Ro 04-6790 Psychopharmacology 2003, 170, 358-367 10.1007/s00213-003-1552-5
17. 6 receptor antagonists with procognitive and antidepressant-like properties ACS Med. Chem. Lett. 2016, 7, 618-622 10.1021/acsmedchemlett.6b00056
18. 6 receptor antagonists in Alzheimer’s disease: Therapeutic rationale and current development status CNS Drugs 2017, 31, 19-32 10.1007/s40263-016-0399-3
19. 6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease J. Med. Chem. 2014, 57, 7160-7181 10.1021/jm5003952
20. Galimberti, D.; Scarpini, E. Idalopirdine as a treatment for Alzheimer’s disease Expert Opin. Invest. Drugs 2015, 24, 981-987 10.1517/13543784.2015.1052402
21. 6 receptor in the rat brain, a study using antisense oligonucleotides J. Pharmacol. Exp. Ther. 1995, 274, 173-180
22. 6 expression in the rat: functional studies using antisense oligonucleotides Behav. Brain Res. 1995, 73, 245-248 10.1016/0166-4328(96)00105-2
23. 6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate Br. J. Pharmacol. 2000, 130, 23-26 10.1038/sj.bjp.0703288
24. Atri, A.; Molinuevo, J. L.; Lemming, O.; Wirth, Y.; Pulte, I.; Wilkinson, D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy Alzheimer's Res. Ther. 2013, 5, 6 10.1186/alzrt160
25. Tariot, P. N.; Farlow, M. R.; Grossberg, G. T.; Graham, S. M.; McDonald, S.; Gergel, I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial J. Am. Med. Assoc. 2004, 291, 317-324 10.1001/jama.291.3.317
26. Lopez, O. L.; Becker, J. T.; Wahed, A. S.; Saxton, J.; Sweet, R. A.; Wolk, D. A.; Klunk, W.; Dekosky, S. T. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease J. Neurol., Neurosurg. Psychiatry 2009, 80, 600-607 10.1136/jnnp.2008.158964
27. LaFerla, F. M.; Martinez-Coria, H.; Green, K. N.; Banerjee, P. K. Combination of memantine and donepezil reverses cognitive deficits in transgenic mice with both amyloid-beta plaques and neurofibrillary tangles Alzheimer's Dementia 2009, 5, e29 10.1016/j.jalz.2009.07.113
28. Parsons, C. G.; Danysz, W.; Dekundy, A.; Pulte, I. Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer’s disease Neurotoxic. Res. 2013, 24, 358-369 10.1007/s12640-013-9398-z
29. Howard, R.; McShane, R.; Lindesay, J.; Ritchie, C.; Baldwin, A.; Barber, R.; Burns, A.; Dening, T.; Findlay, D.; Holmes, C.; Hughes, A.; Jacoby, R.; Jones, R.; McKeith, I.; Macharouthu, A.; O’Brien, J.; Passmore, P.; Sheehan, B.; Juszczak, E.; Katona, C.; Hills, R.; Knapp, M.; Ballard, C.; Brown, R.; Banerjee, S.; Onions, C.; Grif!n, M.; Adams, J.; Gray, R.; Johnson, T.; Bentham, P.; Phillips, P. Donepezil and memantine for moderate-to-severe Alzheimer’s disease N. Engl. J. Med. 2012, 366, 893-903 10.1056/NEJMoa1106668
30. 6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol. 2014, 13, 1092-1099 10.1016/S1474-4422(14)70198-X
31. Axovant Sciences Announces Start Of Confirmatory Phase 3 MINDSET Study And Special Protocol Assessment (SPA) Agreement With FDA; http://investors.axovant.com/investors/press-releases/2015/10-06-2015-120335209; Axovant Sciences Home; http://axovant.com (accessed November 10, 2016).
32. ClinicalTrials.gov; https://clinicaltrials.gov/ct2/show/NCT00895895?term=SAM-531&rank=11 (accessed January 07, 2017).
33. 6 receptor ligands Bioorg. Med. Chem. Lett. 2011, 21, 4577-4580 10.1016/j.bmcl.2011.05.106
34. 6 receptor antagonists Bioorg. Med. Chem. Lett. 2011, 21, 346-349 10.1016/j.bmcl.2010.11.001
35. 6 receptor ligands Bioorg. Med. Chem. Lett. 2012, 22, 7431-7435 10.1016/j.bmcl.2012.10.057
36. 6 receptor ligands ACS Med. Chem. Lett. 2010, 1, 340-344 10.1021/ml100101u
37. 6 receptor antagonists J. Med. Chem. 2012, 55, 9255-9269 10.1021/jm300955x
38. 6 antagonists Bioorg. Med. Chem. Lett. 2000, 10, 2295-2299 10.1016/S0960-894X(00)00453-4
39. 6 receptor ligands J. Med. Chem. 2001, 44, 3881-3895 10.1021/jm010943m
40. 6 receptor agonists and antagonists J. Med. Chem. 2005, 48, 353-356 10.1021/jm049243i
41. Robinson, B. The Fischer indole synthesis Chem. Rev. 1963, 63, 373-401 10.1021/cr60224a003
42. Batcho, A. D.; Leimgruber, W. Indoles from 2-methylnitrobenzenes by condensation with formamide acetals followed by reduction: 4-benzyloxy indole Org. Synth. 1985, 63, 214-220 10.15227/orgsyn.063.0214
43. Kuhn, H.; Stein, O. Über kondensationen von indolen mit aldehyden und sekundären aminen, I. mitteil.: eine neue gramin-synthese Ber. Dtsch. Chem. Ges. B 1937, 70, 567-569 10.1002/cber.19370700330
44. 6 receptor antagonists Bioorg. Med. Chem. Lett. 2005, 15, 379-383 10.1016/j.bmcl.2004.10.064
45. 6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop Mol. Brain Res. 2001, 90, 110-117 10.1016/S0169-328X(01)00090-0
46. 6 receptor-mediated cAMP signaling pathways Br. J. Pharmacol. 2006, 148, 1133-1143 10.1038/sj.bjp.0706827
47. 6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease Neurotherapeutics 2008, 5, 458-469 10.1016/j.nurt.2008.05.008
48. 6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats Int. J. Neuropsychopharmacol. 2010, 13, 1021-1033 10.1017/S1461145710000659
49. 2A receptors reveal conserved transmembrane homology to the human rather than rat sequence Biochim. Biophys. Acta, Biomembr. 1995, 1236, 201-206 10.1016/0005-2736(95)00073-C
50. 2c receptors stimulate amyloid precursor protein ectodomain secretion J. Biol. Chem. 1996, 271, 4188-4194 10.1074/jbc.271.8.4188
51. 2A system: age-, gender-, and Alzheimer’s disease-related findings Neurobiol. Aging 2003, 24, 553-561 10.1016/S0197-4580(02)00137-9
52. 6 receptors in modulating brain neurochemistry Int. Rev. Neurobiol. 2011, 96, 1-26 10.1016/B978-0-12-385902-0.00001-2
53. Nirogi, R.; Kambhampati, R. S.; Shinde, A. K.; Jasti, V. Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate. International Patent Application WO2015/083179-A1, 2015; Suven Life Sciences Limited.
54. Nirogi, R.; Mudigonda, K.; Penta, K.; Bhyrapuneni, G.; Ajjala, D.; Muddana, N.; Palacharla, V. R. C.; Goyal, V. K.; Pandey, S. K.; Abraham, R.; Jayarajan, P.; Badange, R.; Kambhampati, R. Safety, tolerability, and pharmacokinetics of a potent and selective 5-HT6 receptor antagonist, SUVN-502, following multiple ascending doses in healthy elderly subjects, and effect of gender and food on single-dose pharmacokinetics Alzheimer's Dementia 2015, 11, P748 10.1016/j.jalz.2015.06.1669
55. Nirogi, R.; Bhyrapuneni, G.; Kandikere, V.; Benade, V.; Muddana, N.; Saralaya, R.; Irappanavar, S.; Ponnamaneni, R.; Mukkanti, K. Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats Eur. J. Drug Metab. Pharmacokinet. 2012, 37, 155-161 10.1007/s13318-012-0081-1